Literature DB >> 8564357

Long-term survivors of HIV-1 infection.

M R Klein1, F Miedema.   

Abstract

The clinical course and outcome of HIV-1 infection are highly variable. A full spectrum of pathology has been observed, from rapid progression to AIDS within months of HIV-1 seroconversion, to asymptomatic survival for more than a decade. This phenomenon probably reflects the multiphasic and multifactorial nature of the virus-host interactions. Obviously, interest in the extremes now recognized in HIV-1 disease progression is growing, with the hope that mechanisms of protection may be found.

Entities:  

Mesh：

Year:  1995        PMID： 8564357     DOI： 10.1016/s0966-842x(00)88984-2

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  10 in total

1.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.

Authors:  A Oxenius; D A Price; P J Easterbrook; C A O'Callaghan; A D Kelleher; J A Whelan; G Sontag; A K Sewell; R E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

Review 2.  The emerging role of HLA-C in HIV-1 infection.

Authors:  Deanna A Kulpa; Kathleen L Collins
Journal:  Immunology       Date:  2011-10       Impact factor: 7.397

3.  Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Authors:  Stephen A Migueles; Kristin A Weeks; Eric Nou; Amy M Berkley; Julia E Rood; Christine M Osborne; Claire W Hallahan; Nancy A Cogliano-Shutta; Julia A Metcalf; Mary McLaughlin; Richard Kwan; JoAnn M Mican; Richard T Davey; Mark Connors
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

4.  Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences.

Authors:  Morgane Rolland; Nicole Frahm; David C Nickle; Nebojsa Jojic; Wenjie Deng; Todd M Allen; Christian Brander; David E Heckerman; James I Mullins
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

5.  Daily sampling of an HIV-1 patient with slowly progressing disease displays persistence of multiple env subpopulations consistent with neutrality.

Authors:  Helena Skar; Ryan N Gutenkunst; Karin Wilbe Ramsay; Annette Alaeus; Jan Albert; Thomas Leitner
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

6.  Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease course.

Authors:  Daniëlle van Manen; Olivier Delaneau; Neeltje A Kootstra; Brigitte D Boeser-Nunnink; Sophie Limou; Sebastiaan M Bol; Judith A Burger; Aeilko H Zwinderman; Perry D Moerland; Ruben van 't Slot; Jean-François Zagury; Angélique B van 't Wout; Hanneke Schuitemaker
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

7.  Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010.

Authors:  Sundhiya Mandalia; Samantha J Westrop; Eduard J Beck; Mark Nelson; Brian G Gazzard; Nesrina Imami
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

8.  Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.

Authors:  Ellen Van Gulck; Lotte Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander Pasternak; Eric Florence; Guido Vanham
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

9.  Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Authors:  Nesrina Imami; Samantha J Westrop; Nathali Grageda; Anna A Herasimtschuk
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

10.  Factors associated with conversion of long-term non-progressors to progressors: a prospective study of HIV perinatally infected paediatric survivors.

Authors:  Muttineni Radhakrishna; Kharidehal Durga; Ravilla Kondal Rao; Doodipala Mallikarjuna Reddy; Anand Kumar Kondapi
Journal:  Indian J Med Res       Date:  2013-09       Impact factor: 2.375
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.